PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect
Authors:
- L Garcia-OrtiLGL Garcia-Orti
- C CirauquiCCC Cirauqui
- M M AlonsoMAM M Alonso
- M J CalasanzMCM J Calasanz
- M D OderoMOM D Odero
- 14 January 2011
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 25 (4) , 606-614
Abstract
Protein phosphatase 2A (PP2A) is a human tumor suppressor that inhibits cellular transformation by regulating the activity of several signaling proteins critical for malignant cell behavior. PP2A has been described as a potential therapeutic target in chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia and B-cell chronic lymphocytic leukemia. Here, we show that PP2A inactivation is a recurrent event in acute myeloid leukemia (AML), and that restoration of PP2A phosphatase activity by treatment with forskolin in AML cells blocks proliferation, induces caspase-dependent apoptosis and affects AKT and ERK1/2 activity. Moreover, treatment with forskolin had an additive effect with Idarubicin and Ara-c, drugs used in standard induction therapy in AML patients. Analysis at protein level of the PP2A activation status in a series of patients with AML at diagnosis showed PP2A hyperphosphorylation in 78% of cases (29/37). In addition, we found that either deregulated expression of the endogenous PP2A inhibitors SET or CIP2A, overexpression of SETBP1, or downregulation of some PP2A subunits, might be contributing to PP2A inhibition in AML. In conclusion, our results show that PP2A inhibition is a common event in AML cells and that PP2A activators, such as forskolin or FTY720, could represent potential novel therapeutic targets in AML.Keywords
This publication has 56 references indexed in Scilit:
- Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ CancersCancer Research, 2010
- A B56γ mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2AOncogene, 2010
- Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid LeukemiaClinical Cancer Research, 2010
- Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patientsOncogene, 2009
- FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemiaJournal of Clinical Investigation, 2007
- The Tumor Suppressor PP2A Aβ Regulates the RalA GTPaseCell, 2007
- Analysis of 11q22–q23 deletion target genes in B-cell chronic lymphocytic leukaemia: Evidence for a pathogenic role of NPAT, CUL5, and PPP2R1BEuropean Journal of Cancer, 2007
- A specific PP2A regulatory subunit, B56γ, mediates DNA damage‐induced dephosphorylation of p53 at Thr55The EMBO Journal, 2007
- Role for the PP2A/B56δ Phosphatase in Regulating 14-3-3 Release from Cdc25 to Control MitosisCell, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001